Authors
Latest:
Dr. Gogishvili on the Rationale for the EMPOWER-Lung 3 Trial in NSCLCMiranda Gogishvili, MD, discusses the rationale for the phase 3 EMPOWER-Lung 3 trial in advanced or metastatic non–small cell lung cancer.
Latest:
The US Oncology Network Highlights Success With Oncology Care ModelPractices participating in the Oncology Care Model, an experimental payment model developed by the Center for Medicare and Medicaid Innovation, are incentivized to improve patient experiences and outcomes by providing enhanced services and care while bending the total cost curve.
Latest:
Dr Williams on the Evolution of Treatment Approaches in Ovarian CancerHeather R. Williams, MD, discusses the evolution of the ovarian cancer treatment paradigm over the past several decades, as well as the importance of continuing to investigate individualized treatment approaches in this population to expand therapeutic options after disease recurrence.
Latest:
Dr. Owen on Choosing Between BTK Inhibitors in CLLCarolyn Owen, MD, FRCPC, discusses factors to consider when deciding whether to use the BTK inhibitors ibrutinib, acalabrutinib, or zanubrutinib in patients with chronic lymphocytic leukemia.
Latest:
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian CancerLindsey K. Buckingham, MD, discusses an investigation into the use of patient-reported outcomes from the cancer-specific Geriatric Assessment (GA) to predict frailty in women with ovarian cancer, as well as planning the next steps for this research in other gynecologic cancers.
Latest:
Looking Towards The Future of HR+/HER2- Breast CancerThe expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.
Latest:
Ovarian Cancer Prevention With the Opportunistic Salpingectomy: An Opportunity for Multidisciplinary CollaborationA new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.
Latest:
Designer DNA Therapeutic Wipes Out Cancer Stem Cells, Treats Multiple Myeloma in MiceStudy supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma
Latest:
Dr. Wu on the Current Utility of Targeted Therapy in CRCChristina Wu, MD, discusses key targeted therapies under investigation in patients with colorectal cancer.
Latest:
Women in Oncology: Self-Advocacy in a Busy FieldMelinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.
Latest:
Dr. Kunkler on the 10-Year PRIME 2 Data Examining Post-Surgery Radiation in Breast CancerIan Kunkler, FRCP, FRCR, DMRT, MRCP, discusses the 10-year results of the PRIME 2 trial in patients with breast cancer
Latest:
Advanced Biliary Tract Cancers: Novel Biomarker StrategiesClosing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Latest:
Final Thoughts on the Future of Liver CancerA panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.
Latest:
Dr. Chao on Key Trials Leading to FDA Approvals in Metastatic NSCLCYvonne Chao, MD, PhD, discusses key trials leading to FDA approvals in metastatic non–small cell lung cancer.
Latest:
Dr. Blum on Potential of CA-125 as a Biomarker for Renal Medullary CarcinomaKyle A. Blum, MD, MS, says that results from a study of patients renal medullary carcinoma suggest that with CA-125, an established biomarker for ovarian cancer, may play a similar role in this rare disease.
Latest:
Dr Hadoux on the Efficacy of Selpercatinib in RET-Mutant Medullary Thyroid CancerJulien Hadoux, MD, PhD, discusses the efficacy of selpercatinib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer as seen in the phase 3 LIBRETTO-531 trial.
Latest:
Dr Rosner on Personalizing Approaches to Perioperative Therapy in NSCLCSamuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.
Latest:
Dr Kahn on the Investigation of Newcastle Disease Virus With IL-12 in Ovarian CancerRyan Kahn, MD, MHS, discusses the investigation of Newcastle disease virus encoded with interleukin 12 in ovarian cancer.
Latest:
Dr. Xavier on Recent Updates in DLBCLMarin F. Xavier, MD, discusses recent updates in diffuse large B-cell lymphoma based on data from the 2021 ASCO Annual Meeting.
Latest:
Dr. O'Malley on Racial and Economic Barriers to Screening in CRCDenalee O'Malley, PhD, discusses racial and economic barriers to colorectal screening in colorectal cancer.
Latest:
Future of R/R DLBCLA panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.
Latest:
Dr. Vaidya on Advances in the Management of Endometrial CancerAmi P. Vaidya, MD, discusses advances in the management of endometrial cancer.
Latest:
Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCLLori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.
Latest:
Dr. Jain on the Benefit of CDK7 Inhibitors in HR+ Breast CancersAmit Jain, MD, discusses the benefit of CDK7 inhibitors in hormone receptor–positive breast cancers.
Latest:
Future Outlooks in the Treatment of R/R DLBCLShared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
Latest:
Dr West on Adjuvant Endocrine Therapy Plus a CDK4/6 Inhibitor in Early-Stage Breast CancerMalinda West, MD, MS, discusses the use of adjuvant endocrine therapy in combination with CDK4/6 inhibitors in the treatment of patients with early-stage HER2-negative breast cancer.
Latest:
Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of nab-SIROLIMUS for Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)Dr Vinod Ravi talks about nab-SIROLIMUS and reviews the data from the AMPECT trial.
Latest:
Developing Culturally Concordant Palliative Care for Hindu Patients and FamiliesSometimes, clinicians do not acknowledge how patients' values and beliefs influence how they ascribe meaning to their illness, how they prefer to receive information, and how they make decisions until the end-of-life stage, leading to misunderstandings between clinicians and patients.
Latest:
Dr Svoboda on the Implications of Nivolumab Plus AVD in Classical Hodgkin LymphomaJakub Svoboda, MD, discusses the implications of the phase 3 SWOG 1826 trial of nivolumab plus doxorubicin, vinblastine, and dacarbazine in patients with advanced classical Hodgkin lymphoma.
